Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | MMP1 | P03956 | 3/20 | 0.43 |
| ▸ | MMP2 | P08253 | 3/20 | 0.43 |
| ▸ | MMP9 | P14780 | 3/20 | 0.43 |
| ▸ | MMP8 | P22894 | 3/20 | 0.43 |
| ▸ | MMP13 | P45452 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 4/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8535675 | 1.00 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL8531817 | 1.00 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL15648179 | 1.00 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| Ammonia Solution, Strong SCHEMBL1579985 | 0.97 | CA2 (0.41) | CA2CA1MMP1MMP2MMP9 | |
| Ammonia Solution, Strong SCHEMBL6765844 | 0.97 | CA2 (0.41) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL466477 | 0.97 | CA2 (0.41) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL29120349 | 0.92 | CA2 (0.44) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2956524 | 0.92 | CA2 (0.44) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2634716 | 0.92 | CA2 (0.44) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL31261894 | 0.90 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116840388-B | Method for detecting perfluoro and polyfluoroalkyl substances in follicular fluid | 上海交通大学医学院附属新华医院 | 2024-11-22 | — | — | CN | claimed |
| US-20240010524-A1 | COMPOUNDS AND PROCESSES FOR REMEDIATION OF PERFLUOROALKYL | Weaver Labs, LLC | 2024-01-11 | — | — | US | claimed |
| CN-114618445-B | Cotton composite cationic covalent organic framework material and application thereof as solid phase extractant | 青岛理工大学 | 2023-10-24 | — | — | CN | claimed |
| CN-116840388-A | Method for detecting perfluoro and polyfluoroalkyl substances in follicular fluid | 上海交通大学医学院附属新华医院 | 2023-10-03 | — | — | CN | claimed |
| CN-114656642-B | Organic fluorine-silicon emulsion release agent and preparation method thereof | 宁波辉宏新材料有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-113214120-B | Preparation method of perfluorohexyl ethyl sulfonate | 四川上氟科技有限公司 | 2022-10-04 | — | — | CN | claimed |
| CN-113214120-A | Preparation method of perfluorohexyl ethyl sulfonate | 四川上氟科技有限公司 | 2021-08-06 | — | — | CN | claimed |
| CN-1690096-B | Method of producing thermoplastic fluoropolymers using alkyl sulfonate surfactants | ARKEMA INC | 2011-05-25 | — | — | CN | claimed |
| CN-1690096-A | Method of producing thermoplastic fluoropolymers using alkyl sulfonate surfactants | ARKEMA INC (US) | 2005-11-02 | — | — | CN | claimed |
| WO-2026102266-A1 | ACTIVATED CARBON COMPOSITE AND METHOD OF REMOVING CONTAMINANT | BIRCHTECH CORP. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260131306-A1 | ACTIVATED CARBON COMPOSITE AND METHOD OF REMOVING CONTAMINANT | BIRCHTECH CORP (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260078029-A1 | TREATMENT OF AQUEOUS COMPOSITION WITH METAL COMPONENT | NUQUATIC LLC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4688667-A2 | TREATMENT OF AQUEOUS COMPOSITION WITH METAL COMPONENT | NuQuatic, LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4662252-A1 | METHOD FOR MANUFACTURING FLUOROELASTOMERS | Syensqo Specialty Polymers Italy S.p.A. (IT) | 2025-12-17 | — | — | EP | disclosed |
| US-5789508-A | Polymerization process | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0847407-A1 | TETRAFLUORETHYLENE POLYMERIZATION PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-06-17 | — | — | EP | disclosed |
| EP-0808336-A2 | AMORPHOUS COPOLYMERS OF TETRAFLUOROETHYLENE AND HEXAFLUOROPROPYLENE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-11-26 | — | — | EP | disclosed |
| US-5688884-A | Polymerization process | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-11-18 | — | — | US | disclosed |
| WO-1997008214-A1 | TETRAFLUORETHYLENE POLYMERIZATION PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-03-06 | — | — | WO | disclosed |
| WO-1996024625-A2 | AMORPHOUS COPOLYMERS OF TETRAFLUOROETHYLENE AND HEXAFLUOROPROPYLENE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131306-A1 | ACTIVATED CARBON COMPOSITE AND METHOD OF REMOVING CONTAMINANT | SCO2, CNPY2, PCK1 | CA2 33/4885CA1 191/4885MMP1 4605/4885 |
| US-20240010524-A1 | COMPOUNDS AND PROCESSES FOR REMEDIATION OF PERFLUOROALKYL | PFAS, FGB, FGR | CA2 2098/4885CA1 1360/4885MMP1 1524/4885 |
| US-20260078029-A1 | TREATMENT OF AQUEOUS COMPOSITION WITH METAL COMPONENT | F8, SLC39A3, SLC39A14 | CA2 100/4885CA1 206/4885MMP1 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.